ABSTRACT
INTRODUCTION
Angiogenesis, the forming of new blood vessels, plays a crucial role in many physiological and pathologic processes, including tumor growth, rheumatoid arthritis and diabetic retinopathies. Vascular endothelial growth factor (VEGF), released by tumor cells, is an important growth factor in tumor angiogenesis (Lin et al., 1999; Nagengast et al., 2007) . Considering the critical role of VEGF in tumour development and recent reports on the positive impact of VEGF targeted therapy, it has became one of the most exciting fields of cancer investigation. A number of strategies have been pursued to target the VEGF, including monoclonal antibodies and soluble forms of the VEGF receptor (Jimeno and Funes, 2005) . Monoclonal antibodies were used to prevent the activity of the VEGF. These molecules have been the most effective tools used in the treatment of cancer (Ruddon, 2007) . Studies have focused on the use of radionuclide antibody conjugates since these reagents offer the potential for both therapy and specific nuclear imaging (Ruegg et al., 1990; Ünak, 2002) . Bevacizumab is a recombinant, humanized monoclonal antibody directed against VEGF. It blocks VEGF induced tumor angiogenesis by binding, thereby neutralizing VEGF (Lin et al. 1999; Nagengast et al., 2007) . It has an antitumor potential on metastatic colon carcinoma, non small cell lung cancer, breast, pancreas, prostate, ovary, urinary and central nervous system tumors (Papatsoris et al., 2005; Heinemann et al., 2009; Patel et al., 2009) . The combination of anti-VEGF antibody and chemotherapy in nude mice having human cancer xenografts has greater influence than chemotherapy alone or the antibody alone (Marty et al., 2006) . To date, Bevacizumab has been labeled with different radionuclides.
89 Zr and 111 In labeling of Bevacizumab resulted in high labeling efficiencies and adequate preservation of VEGF binding properties by using human ovarian cancer (SKOV-3) bearing athymic nude mice (Nagengast et al., 2007) . 125 I-Bevacizumab was developed to inhibit the effects of VEGF in the treatment of solid tumors (Lin et al., 1999) . Abbas et al. (2008) 
Synthesis of BevMab-DTPA
The synthesis of BevMab-DTPA was performed according to Nagengast et al., 2007 with some modifications (Nagengast et al., 2007) . BevMab was purified from other excipients by ultrafiltration (Vivaspin-2 Sartarious, Germany) and diluted in water for injection to 5 mg/mL. The crude product (purified BevMab) was stored at -20 0 C. Five mg of purified Bevacizumab was conjugated with DTPA. To obtain a hydrophilic anti angiogenic compound, 5 mg of purified Bevacizumab was adjusted to pH 9.5 (50 mmol/ L Na 2 CO 3 , pH 9.5) and 50 M excess DTPA was added. After 1 h incubation at room temperature, the mixture was purified by ultracentrifugation with ammonium acetate (50 mmol/L, pH 5.5) to eliminate the excess unconjugated DTPA. Purified conjugated Bevacizumab (BevMab-DTPA) was diluted (5 mg/mL) in ammonium acetate and stored at -20 0 C in the dark until the analysis (Fig.1) . -and 50 µL of SnCl 2 (1 mg SnCl 2 .2H 2 O in 1 mL HCl) into 100 µg (150 µL) of BevMab-DTPA solution. The pH was adjusted to 5 with 1 M NaOH solution. The reaction mixture was shaken and allowed to stand for 30 min at room temperature.
Quality control procedures High Performance Liquid Radio Chromatography (HPLRC)
A low pressure gradient HPLC system (LC10ATvp quaternary pump, SPD-10A/V UV detector, a syringe injector equipped with a 1 mL loop and 7-µm VP 250/21 Nucleosil 100-7 C18 column (Macherey -Nagel) was used for the the prufication experiments. The eluante was collected with a FRC-10A fraction collector (Shimadzu), equipped with a RAD501 single channel analyzer, having a Cd (Te) solid-state detector. The flow rate was set to 5.0 mL/min. A 5-µm EC 250/4.6 Nucleodur 100-5 C18 column (Macherey -Nagel) and a syringe injector equipped with a 20 µL loop was used. The flow rate was set to 1.0 mL/min. UV detection was achieved at 240 nm and 280 nm. The mobile phase system consisted of 40% water -60% acetonitrile.
Thin Layer Radio Chromatography (TLRC)
TLRC was performed with ITLC-SG (Merck-5554) using 1.5x10 cm size plates. The samples of 99m Tc-BevMab-DTPA (5 µL) were applied. TLRC solvent (0.004 M ammonium acetate / methanol 9:1 v/v) was used as mobile phase 1 and SF (% 0.9 NaCl) was used as mobile phase 2 to determine the radiochemical purity. Then, the TLRC plates were counted by TLC Scanner (BioscanAR 2000). The R f values and labeling yield were determined.
Stability study of 99m
Tc-BevMab-DTPA in human serum In vitro stability of 99m Tc-BevMab-DTPA in human serum was determined by incubating (66.66 µg) 100 µL of the labeled compound with 300 µL of human serum at 37 0 C. The aliquots were then analyzed at time intervals of 30, 60, 240 and 1440 minutes by TLRC after labeling and their radioactivities were measured.
Determination of the partition coefficient (logP)
for the complex Lipophilicity (logP) of the radiotracer was measured as follows: 0.1 mL of 99m Tc radiolabeled compound was added to an equal volume of 1-octanol and phosphate buffer (pH 7.0) in a centrifuge tube. The resulting solution was mixed for 1 min and centrifuged for 30 min at 2500 rpm. The radioactivity of each layer was counted by Cd(Te) detector. Each measurement was repeated three times. The partition coefficient, P, was calculated using the equation; P = (cpm in octanolcpm in background) / (cpm in buffer-cpm in background) (Biber et al., 2010) . The final partition coefficient value was usually expressed as log P. Theoretical log P calculations were done with ACD/logP software (Version 6.0 for Microsoft Windows).
Biodistribution studies on female and male Albino Wistar rats
Experiments with animals were approved by the Institutional Animal Review Committee of Ege University. 99m Tc labeled product was sterilized by passing through a 0.22 µm membrane filter. Then, it was injected into the tail vein of nine female and nine male albino Wistar rats (4 µg / each rat), which were 150-200 g in weight. They were maintained under controlled room conditions (22±5 0 C, 12 h of light/dark cycle), water and normal diet (adlibitum). The activity was approximately 400 µCi (0.2 mL)/ each rat. The rats were sacrificed at 60, 240 and 420 minutes postinjection under sodium penta borate anesthesia and tissues of interest were removed. Blood samples were taken, and the organs were excised. All the tissues were weighed and counted by Cd(Te) detector. The percent of radioactivity per gram of tissue weight (% injected activity / g tissue) was determined. Tc-BevMab-DTPA from Cd (Te) detector. Tc-BevMab-DTPA existed as an intact complex in human serum up to 1440 minutes (Fig.  3) . Tc-BevMab-DTPA (-1.14 ± 0.18) was different from logP value of Tc-DTPA (-1.08 ± 0.20) according to ACD/lopP Algorithm programme. It is known that monoclonal antibodies are lipophilic compounds that are distributed throughout the body. The lipophilicity of BevMab was reduced by DTPA conjugation in this study. have reported that, chelate charge and lipophilicity might play an important role in biologic behavior. It is also known that the bifunctional chelating agent (BFCA) can profoundly influence the biodistribution pattern and excretory route, and this in vivo behavior can be predicted somewhat by the in vitro measurement of parameters such as stability and lipophilicity (Schmitt et al., 2005; Decristoforo et al., 2000) . These results were confirmed by some others also (Ertay et al., 2005; . Biodistribution of 99m Tc-BevMab-DTPA as % Injected dose /g organ (%ID/g organ) for female and male rats are given in Figures 4 and 5 The distribution figures demonstrated that the radiolabeled compound was eliminated through the kidneys and accumulated in urine bladder in both the female and male rats. This was with 0.5 % ID/g almost the same for both the sexes. It is known that DTPA excretes through kidneys (Trejtnar and Laznicek, 2002) . Conjugation of BevMab with DTPA gives the molecule a less lipophilic and more hydrophilic structure, which promotes the elimination through the kidney. As demonstrated in Figure 4 and 5, the values of the BevMab-DTPA uptakes were similar in heart, blood, liver and spleen in both the sexes. Large intestines uptakes in the male rats were significantly higher (p<0.05). Compared to 240 min (0.07 %ID/g and 0.83 %ID/g), 11.85 times more activities were observed at 420 min postinjection (Fig. 5) . Figure 5 also demonstrated that the radiolabeled compound had accumulated in the stomach together with large intestines up to 420 th minutes. No significant radioactivity uptakes were observed in the testis. In the prostate, the 60 min uptake activity was 12.25 times higher than 240 min, and 6.12 times higher than 420 min values. Statistical analysis according to Pearson corelation supported the biodistribution results (P<0.05). The highest uptake activities were observed in the stomach of both the sexes. With the DTPA, a more hydrophilic derivative of BevMab was generated. The uptake of labeled BevMab-DTPA in stomach for the female rats (25.57%ID/g (P<0.05)) reached maximun at 60 min. The uptakes decreased with time. On the other hand, the highest uptake in the stomach for the male rats (18.22%ID/g (P<0.05)) was observed at 60 min. The stomach uptake of the female rats were significantly higher than the male rats' stomach at 60 and 240 min (Figs 4 and 5, respectively). Female rats' stomach presented 18 times higher uptake activity compared to male rats' stomach at 240 min postinjection particularly. This high stomach uptake for both the sexes could be due to the fenestration found on the capillary endothelial of endocrine organs, gastrointestinal system, kidney glomeruli and in some areas of brain (Roberts and Palade 1997; Esser et al., 1998) . Tc-BevMab-DTPA is a less lipophilic structure which promotes the elimination through the kidney. Pillai et al. (1999) have similarly found that the compounds of carboxylic acid were more hydrophilic and eliminated through the kidney. However, the data demonstrated that the male rats had three times faster elimination in the first hour than the female rats (1.57 and 0.48%ID/g, respectively). The elimination of BevMab-DTPA was similar in both the sexes at 240 and 420 minutes. It has been reported that VEGF is found in the heart, testis and kidneys (Jakeman et al., 1992) . Lin and coworkers (1999) have demonstrated that 125 I labeled BevMab showed high radioactivity at 48 h postinjection in the heart and testis of healthy rabbits, together with their urine bladder and kidney. This could be due to the reason that the hydrophilic analogues are less uptaken by the liver and lung to the hydrophobic compounds (Delpassand et al., 1996) . Another report showed that 213 Bi-bevacizumab had high renal uptake but low liver and spleen uptake (Abbas et al., 2008) .
Statistical analysis

CONCLUSIONS
The radiolabeled yield of BevMab-DTPA was over 95% and it was stable during the period at 37 0 C in human serum media. Further studies with animal models with tumors and cell culture experiments should be done in order to explore if 99m Tc-BevMab-DTPA could be used as an in vivo VEGF imaging agent, early tumor detection and inhibition of tumor growth.
